Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mRNA flu shot shows promise in early trial

NCT ID NCT06436703

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Pfizer completed a study testing a new modified RNA (mRNA) flu vaccine in 1,202 healthy adults aged 18 and older. The goal was to see if the vaccine is safe and triggers a strong immune response. Participants received either the experimental mRNA vaccine or a licensed flu shot, and were followed for about 6 months. This early research helps determine whether mRNA technology can improve flu protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified RNA influenza vaccine
What this could lead to
If successful, this could lead to a more effective or faster-to-update flu vaccine, potentially offering better protection each season.
What could go wrong
This was an early-phase study focused on safety and immune response, not on preventing flu illness. The vaccine may not work better than existing flu shots, and side effects like injection-site pain or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

1,202 people

The number who actually took part.

Started

May 2024

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria Applies to all 3 substudies: * participants ≥18 years of age. * generally healthy participants. Substudy C ONLY: \- receipt of licensed influenza vaccination for the 2023-2024 flu season at least 6 months ago. Key Exclusion Criteria All 3 substudies: * diagnosis of influenza (by clinical testing) in the last 6 months. * immunocompromised individuals with known or suspected immunodeficiency * receipt of any investigational or licensed influenza vaccines within 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza, human are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza, human

Contacts and locations

Locations

  • AMR Clinical

    Mobile, Alabama, 36608, United States

  • AMR Clinical

    Norfolk, Virginia, 23502, United States

  • Alliance for Multispecialty Research, LLC

    New Orleans, Louisiana, 70119, United States

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri, 64114, United States

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States

  • Artemis Institute for Clinical Research

    San Diego, California, 92103, United States

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911, United States

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801, United States

  • Clinical Research Consulting

    Milford, Connecticut, 06460, United States

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • Clinical Trials of Texas, LLC

    San Antonio, Texas, 78229, United States

  • Clinical Trials of Texas, LLC dba Flourish Research

    San Antonio, Texas, 78229, United States

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania, 19107, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Duke Vaccine and Trials Unit

    Durham, North Carolina, 27703, United States

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Tomball, Texas, 77375, United States

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814, United States

  • Headlands Horizons LLC

    Brownsville, Texas, 78526, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • Headlands Research Orlando

    Orlando, Florida, 32819, United States

  • Indago Research & Health Center, Inc

    Hialeah, Florida, 33012, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah, 84109, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah, 84121, United States

  • M3 Wake Research, Inc.

    Raleigh, North Carolina, 27612, United States

  • Orange County Research Center

    Lake Forest, California, 92630, United States

  • Palm Springs Community Health Center

    Miami Lakes, Florida, 33014, United States

  • Prism Research LLC dba Nucleus Network

    Saint Paul, Minnesota, 55114, United States

  • Qps-Mra, Llc

    South Miami, Florida, 33143, United States

  • Research Centers of America

    Hollywood, Florida, 33024, United States

  • Research Centers of America ( Hollywood )

    Hollywood, Florida, 33024, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

  • SMS Clinical Research

    Mesquite, Texas, 75149, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.